Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$291.64 CAD
Change Today +6.41 / 2.25%
Volume 590.4K
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Mexico
Frankfurt
As of 4:00 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Snapshot

Open
C$286.70
Previous Close
C$285.23
Day High
C$292.96
Day Low
C$284.92
52 Week High
05/22/15 - C$292.96
52 Week Low
08/11/14 - C$116.01
Market Cap
99.4B
Average Volume 10 Days
633.3K
EPS TTM
C$2.75
Shares Outstanding
340.9M
EX-Date
11/10/10
P/E TM
86.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for VALEANT PHARMACEUTICALS INTE (VRX)

valeant pharmaceuticals inte (VRX) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

16,800 Employees
Last Reported Date: 02/25/15
Founded in 1983

valeant pharmaceuticals inte (VRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.9M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $953.8K
President of Valeant Europe and General Manag...
Total Annual Compensation: $499.3K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $5.8M
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $715.4K
Compensation as of Fiscal Year 2014.

valeant pharmaceuticals inte (VRX) Key Developments

Valeant Pharmaceuticals International Mulls Acquisitions

Valeant Pharmaceuticals International, Inc. (TSX:VRX) is seeking acquisitions.

Valeant Pharmaceuticals International, Inc. - Shareholder/Analyst Call

Annual Meeting of Shareholders

Valeant Pharmaceuticals International, Inc. Announces Management Changes

On April 29, 2015, Valeant Pharmaceuticals International, Inc. announced that Howard B. Schiller intends to resign as Executive Vice President and Chief Financial Officer, effective at such time that his successor is appointed. Mr. Schiller will continue to serve on the company's Board of Directors and, with the Board's continued recommendation of Mr. Schiller as a nominee for re-election to the Board, Mr. Schiller intends to stand for re-election at the company's 2015 annual shareholder meeting. The company also announced that Anne C. Whitaker, former President and Chief Executive Officer of Synta Pharmaceuticals, will join Valeant's Executive Management Team as Executive Vice President and Company Group Chairman.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$291.64 CAD +6.41

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $301.35 USD +0.13
Astellas Pharma Inc ¥1,821 JPY -0.50
Bristol-Myers Squibb Co $68.30 USD -0.59
Mylan NV $69.66 USD -0.28
Sun Pharmaceutical Industries Ltd 1,004 INR 0.00
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 80.8x
Price/Sales 9.3x
Price/Book 12.6x
Price/Cash Flow 32.6x
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.